Australia Cerebral Infarction Treatment Market Size & Outlook
Related Markets
Australia cerebral infarction treatment market highlights
- The Australia cerebral infarction treatment market generated a revenue of USD 463.2 million in 2024 and is expected to reach USD 743.3 million by 2030.
- The Australia market is expected to grow at a CAGR of 8.2% from 2025 to 2030.
- In terms of segment, tissue plasminogen activators (tpa) was the largest revenue generating drug class in 2024.
- Anticoagulants is the most lucrative drug class segment registering the fastest growth during the forecast period.
Cerebral infarction treatment market data book summary
| Market revenue in 2024 | USD 463.2 million |
| Market revenue in 2030 | USD 743.3 million |
| Growth rate | 8.2% (CAGR from 2025 to 2030) |
| Largest segment | Tissue plasminogen activators (tpa) |
| Fastest growing segment | Anticoagulants |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tissue Plasminogen Activators (tPA), Anticoagulants, Antiplatelets, Anticonvulsants |
Other key industry trends
- In terms of revenue, Australia accounted for 3.5% of the global cerebral infarction treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China cerebral infarction treatment market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 312.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cerebral Infarction Treatment Market Scope
Cerebral Infarction Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amneal Pharmaceuticals Inc Ordinary Shares - Class A | View profile | 7700 | 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, United States, 08807 | https://www.amneal.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Otsuka Holdings Co Ltd | View profile | 39548 | 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo, Japan, 101-0048 | http://www.otsuka.com/jp |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Australia cerebral infarction treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cerebral infarction treatment market will help companies and investors design strategic landscapes.
Tissue plasminogen activators (tpa) was the largest segment with a revenue share of 39.25% in 2024. Horizon Databook has segmented the Australia cerebral infarction treatment market based on tissue plasminogen activators (tpa), anticoagulants, antiplatelets, anticonvulsants covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Australia cerebral infarction treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia cerebral infarction treatment market databook
-
Our clientele includes a mix of cerebral infarction treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia cerebral infarction treatment market , including forecasts for subscribers. This country databook contains high-level insights into Australia cerebral infarction treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia Drug Class - Cerebral Infarction Treatment Market size, 2024 - 2030 (US$M)
Australia Cerebral Infarction Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
